Figure 2
From: Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). CLASI shows a reduction of the CLASI activity (CLASI A (●)) score with no significant changes in the CLASI damage (CLASI D (■)) score over 12 months of follow-up. A significant improvement of the inflammatory rash was already observed by week 2. Data is expressed as mean ± SEM. *P value refers to the comparison of CLASI scores between two weeks after treatment and baseline.
